Saturday - May 3, 2025
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. Starting at 5:00 p.m. EDT on May 9, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.
Conference Call Information
When: Thursday, May 9, 2024, starting at 5:00 p.m. Eastern Daylight Time
To access the conference call:
Dial: (800) 715-9871 (toll-free USA and Canada); (646) 307-1963 (international)
Conference ID: 4442005
Webcast: https://edge.media-server.com/mmc/p/jqq7phbt/
The press release with the first quarter 2024 financial results and related materials will be available at https://investors.coherus.com before the start of the conference call.
A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations.
Please dial in 15 minutes early to ensure a timely connection to the call.
Disclosure Information
Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Coherus Contact Information
Investors:
Jami Taylor, Head of Investor Relations for Coherus
IR@coherus.com
Last Trade: | US$1.10 |
Daily Change: | 0.05 4.76 |
Daily Volume: | 1,736,899 |
Market Cap: | US$126.730M |
March 10, 2025 January 22, 2025 January 08, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load